Optimize Rx Corp OPRX
We take great care to ensure that the data presented and summarized in this overview for OptimizeRx Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OPRX
View all-
First Light Asset Management, LLC Edina, MN1.81MShares$9.87 Million1.22% of portfolio
-
Black Rock Inc. New York, NY1.18MShares$6.41 Million0.0% of portfolio
-
Awm Investment Company, Inc. New York, NY1.07MShares$5.84 Million1.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA953KShares$5.19 Million0.0% of portfolio
-
Blair William & CO Chicago, IL677KShares$3.69 Million0.02% of portfolio
-
Rice Hall James & Associates, LLC615KShares$3.35 Million0.28% of portfolio
-
Dimensional Fund Advisors LP Austin, TX404KShares$2.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA396KShares$2.16 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO376KShares$2.05 Million0.07% of portfolio
-
Jacob Asset Management Of New York LLC Hermosa Beach, CA370KShares$2.02 Million4.08% of portfolio
Latest Institutional Activity in OPRX
Top Purchases
Top Sells
About OPRX
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
Insider Transactions at OPRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 12
2024
|
William J Febbo CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+3.22%
|
$100,000
$5.01 P/Share
|
Nov 08
2024
|
Marion Odence Ford General Counsel and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-2.1%
|
$3,144
$6.27 P/Share
|
Nov 08
2024
|
Marion Odence Ford General Counsel and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,785
+6.67%
|
-
|
Nov 01
2024
|
Theresa Greco Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,693
-4.57%
|
$8,465
$5.15 P/Share
|
Oct 11
2024
|
Edward Stelmakh CFO/COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,066
-5.83%
|
$12,396
$6.63 P/Share
|
Oct 11
2024
|
Edward Stelmakh CFO/COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,222
+18.83%
|
-
|
Oct 03
2024
|
Edward Stelmakh CFO/COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,177
-13.31%
|
$29,239
$7.83 P/Share
|
Oct 03
2024
|
Edward Stelmakh CFO/COO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,622
+34.62%
|
-
|
Oct 03
2024
|
Stephen L Silvestro Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,617
-3.29%
|
$18,319
$7.83 P/Share
|
Oct 03
2024
|
Stephen L Silvestro Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,649
+7.72%
|
-
|
Oct 03
2024
|
Marion Odence Ford General Counsel and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,952
-7.76%
|
$13,664
$7.83 P/Share
|
Oct 03
2024
|
Marion Odence Ford General Counsel and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,649
+20.91%
|
-
|
Oct 03
2024
|
Doug Besch Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
976
-8.74%
|
$6,832
$7.83 P/Share
|
Oct 03
2024
|
Doug Besch Chief Product Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,324
+22.93%
|
-
|
Jun 07
2024
|
Ellen O'Connor Vos Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+17.47%
|
-
|
Jun 07
2024
|
Patrick D Spangler Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+22.61%
|
-
|
Jun 07
2024
|
James Paul Lang Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+16.34%
|
-
|
Jun 07
2024
|
Cathy Klema Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,643
+50.0%
|
-
|
Jun 07
2024
|
Gregory D Wasson Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+21.92%
|
-
|
Jun 05
2024
|
Ellen O'Connor Vos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,061
+16.9%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 158K shares |
---|---|
Exercise of conversion of derivative security | 229K shares |
Open market or private purchase | 20K shares |
Payment of exercise price or tax liability | 55.4K shares |
---|---|
Open market or private sale | 4K shares |